Crohn's disease is a type of inflammatory bowel disease (IBD). It causes inflammation of the digestive tract, which can lead to abdominal pain, severe diarrhea, fatigue, weight loss and malnutrition. Inflammation caused by Crohn's disease can involve different areas of the digestive tract in different people.
Investigators
Open Research Studies for Crohn's Disease
AbbVie AFFIRM
Enrolling: Yes
Principle Investigator: Monika Fischer, MD
Duration: 49 weeks, 11 visits
Patient Population: Adult patients with a diagnosis of Crohn's Disease
Interested in this study? Please contact the IBD research team: iuibd@iu.edu
SPARC IBD
Enrolling: Yes
Principle Investigator: Satya Kurada, MD
Duration: All bio-specimen collections and chart reviews will continue until 2026
Patient Population: Any patient with either Crohn’s Disease or Ulcerative Colitis
Study Intervention: Medical chart reviews and biological specimen collection.
Interested in this study? Please contact the IBD research team: iuibd@iu.edu
Closed Crohn's Disease Studies
Duration: 12 Weeks + potential to receive treatment for up to 4.5 years
Patient Population: Adult patients with moderately to severely active Crohn’s disease
Study Intervention: Ozanimod (Oral)
Possibility of Placebo: 1 in 3
Duration: 32-66 weeks + Long-term Extension (Approx. 8-13 clinic visits)
Patient Population: Adult patients with moderately to severely active Crohn’s disease
Study Intervention: Filgotinib (Oral)
Possibility of Placebo: 1 in 3
Duration: 3 years (2 in person visits)
Patient Population: Adult patients with newly (within 5 years) diagnosed Crohn's Disease and no disease-related complications.
Duration: One time scan (1 in person visit)
Patient Population: Adult patients with Crohn's Disease or Ulcerative Colitis fasting for 2 hours prior
Duration: Indefinite or upon withdraw
Patient Population: Any patient with either Crohn’s Disease or Ulcerative Colitis
Study Procedures: Patient surveys before every office visit & medical chart reviews
Duration: 1 year (16 in person visits)
Patient Population: Adult patients with moderately to severely active Crohn’s disease
Study Intervention: Oral BI 706321 + Stelara
Possibility of Placebo: Yes
Duration: 16 weeks
Patient Population: Adult patients with mild to moderate Crohn's Disease and on a stable dose of medication
Study Intervention: 3 self-provided vagal nerve stimulations per day for 16 weeks
Possibility of Placebo: None
Duration: 1 year – Option to roll into the long term extension study VIVID-2
Patient Population: Adult patients with moderately to severely active Crohn’s disease
Study Intervention: Mirikizumab vs Stelara vs Placebo
Possibility of Placebo: 2 in 11
Duration: Approximately 112 weeks
Patient Population: Adult patients with moderately to severely active Crohn’s disease
Study Intervention: BMS-986165 (oral)
Possibility of Placebo: 1 in 4
Duration: 48 weeks + potential to receive up to 2 additional years of treatment
Patient Population: Adult patients with moderately to severely active Crohn’s disease
Study Intervention: Guselkumab or Ustekinumab ( IV + Subcutaneous)
Possibility of Placebo: 1 in 5